BioCentury
ARTICLE | Company News

Repligen diagnostic, neurology news

August 6, 2012 7:00 AM UTC

Repligen disclosed in its 2Q12 earnings that it will now seek to partner its therapeutic product pipeline to focus resources on expanding its bioprocessing business, which recorded 2Q12 revenue of $11.7 million. The company's pipeline includes pancreatic imaging agent SecreFlo ( RG1068), for which FDA issued a complete response letter in June asking for an additional clinical trial, as well as two products in Phase I testing: RG2833 for Friedreich's ataxia; and RG3039 for spinal muscular atrophy (SMA). SecreFlo is a synthetic human secretin. RG2833 is a selective histone deacetylase 3 (HDAC3) inhibitor and RG3039 is a small molecule inhibitor of decapping enzyme scavenger (DCPS) (see BioCentury, June 25). ...